Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs”). In June 2024, the evaluation of BNT327/PM8002 in combination with BNT325/DB-1305, a ...

Upon closing, BioNTech will gain full rights to Biotheus’ pipeline candidates and its in-house bispecific antibody drug conjugate capability. The acquisition will expand BioNTech’s footprint in China, ...

The theory behind antibody drug conjugates (ADCs ... trials We see the efficacy of ADCs being tested in cancers less responsive to checkpoint inhibitors (i.e. “cold tumours” in pancreatic ...

BioNTech said that BNT327 has the "potential to replace current checkpoint inhibitor standard of care treatments for solid ...

Additional trials will explore combining BNT327/PM8002 and BioNTech’s proprietary antibody-drug conjugates (“ADCs ... PD-L1-low and -negative tumors who have typically been less responsive to current ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

In treatment block A, patients initially receive a novel experimental treatment of the antibody-drug conjugate datopotamab deruxtecan ... durvalumab showed promising results in the HER2-immune ...

About Ozuriftamab Vedotin Ozuriftamab vedotin, CAB-ROR2-ADC, is a conditionally and reversibly active antibody drug conjugate directed against ROR2 ... solid tumor indications that are known to be ...

As pharmaceutical companies embrace antibody-drug conjugates (ADCs) as a way to treat cancer, drug services providers are ...